Innovative Health Solutions filed an SEC Form D to confirm the sale of a debt and equity offering worth a total of $4 million. The Versailles, Ind.–based noninvasive neurostimulation company completed the filing last week, after the first sale of the new notice was made on Sept. 6. Innovative Health listed the total amount at […]
This injectable electrode could lower the cost of neuromodulation therapy
Researchers at the University of Wisconsin-Madison have developed an injectable, flexible electrode that could replace rigid nerve-stimulating implants and reduce the cost of neuromodulation therapy. The researchers’s new type of electrode can be injected as a liquid and cure within the body. Traditional neuromodulation treatments require surgically implanted devices that can cost up to six […]
Axonics slides on earnings, misses on revenue in Q3 results
Axonics Modulation Technologies (NSDQ:AXNX) posted third-quarter results today that missed the consensus forecast on Wall Street. The Irvine, Calif.-based company posted losses of $25 million, or -89¢ per share, on sales of $1.3 million for the three months ended Sept. 30, 2019, for a bottom-line loss of 228.9% sales growth of 546.8% compared with Q3 2018. […]
Axonics wins FDA approval for sacral neuromodulation device
Axonics Modulation Technologies (NSDQ:AXNX) announced today that it won FDA premarket approval for its r-SNM sacral neuromodulation system for the treatment of overactive bladder and urinary retention. The implantable, rechargeable sacral neuromodulation device is the first of its kind approved for sale in the U.S., Europe, Canada and Australia. It is also the only SNM device […]
Nevro launches Senza Omnia spinal cord stimulation system
Nevro (NYSE:NVRO) said today that it won FDA approval for and launched its Senza Omnia spinal cord stimulation system. The Senza Omnia is the first and only SCS system designed to deliver Nevro’s proprietary HF10 therapy, as well as other available SCS frequencies, Nevro said in a news release. Redwood City, Calif.–based Nevro’s Omnia system is […]
Neuromod developer ENeura sells nearly $6 million in debt
ENeura Therapeutics, a neuromod developer, today filed an SEC Form D to confirm the sale of nearly $6 million in a debt offering. The new notice’s first sale was made last week. The Baltimore-based company does not intend for the offering to last for more than one year. ENeura’s offering total was set at nearly […]
Medtronic launches Activa DBS programmer
Medtronic (NYSE:MDT) said yesterday that it commercially launched its Activa patient programmer technology for deep brain stimulation in the U.S. The programmer won FDA approval in July and is designed to combine with a Samsung mobile device to allow patients to manage DBS therapy in a simple and discrete way. Medtronic said more than 150,000 patients […]
Neuronetics inks deal with TMS provider for NeuroStar depression device
Neuronetics (NSDQ:STIM) said today that it entered into a partnership with Success TMS to offer Neuronetics’ NeuroStar advanced therapy system as its preferred transcranial magnetic stimulation device across six states. The NeuroStar system is designed to use strong magnetic fields to stimulate areas of the brain associated with mood in the treatment of patients with […]
ShiraTronics raises $33m Series A for migraine neuromod program
ShiraTronics said yesterday that it completed a $33 million Series A financing round for the migraine headache neuromodulation treatment it’s developing and announced the appointment of Lynn Elliott as president & CEO. Elliott is a three-decade veteran of the industry, having previously worked at Guidant, Boston Scientific and Spinal Modulation before assuming his new role […]
The top 10 medical disruptors of 2020
For the past 17 years, the Cleveland Clinic has predicted what the top 10 medical disruptors will be for the following year. The list of technologies, cultivated by a panel of physicians and scientists at the clinic, was led by Dr. Michael Roizen, emeritus chief wellness officer. “Healthcare is ever-changing and we anticipate that these […]
DeviceTalks Q&A: Talking targeted pain management with CEO Maria Bennett
At DeviceTalks Minnesota 2019, SPR Therapeutics founder, president & CEO Maria Bennett spoke with DeviceTalks program manager Sarah Faulkner about the company’s FDA-cleared peripheral nerve stimulation system for pain management. Want to see these interviews live? Join us at DeviceTalks West – Dec. 9-10 in Santa Clara, Calif. Sarah: Could you tell us a little […]
- 1
- 2
- 3
- …
- 81
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube